Oncology Institute (TOI) Competitors

$3.98 -0.10 (-2.45%)

Closing price 04:00 PM Eastern

Extended Trading

$4.00 +0.02 (+0.50%)

As of 07:01 PM Eastern

TOI vs. INNV, CDNA, TDOC, PNTG, and FTRE

Should you be buying Oncology Institute stock or one of its competitors? The main competitors of Oncology Institute include InnovAge (INNV), CareDx (CDNA), Teladoc Health (TDOC), The Pennant Group (PNTG), and Fortrea (FTRE). These companies are all part of the "healthcare" industry.

How does Oncology Institute compare to InnovAge?

InnovAge (NASDAQ:INNV) and Oncology Institute (NASDAQ:TOI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership.

: InnovAge has a net margin of 0.71% compared to Oncology Institute's net margin of -11.45%. InnovAge's return on equity of 2.60% beat Oncology Institute's return on equity.
Company Net Margins Return on Equity Return on Assets
InnovAge 0.71% 2.60% 1.23%
Oncology Institute -11.45% N/A -33.70%
: In the previous week, InnovAge had 5 more articles in the media than Oncology Institute. MarketBeat recorded 7 mentions for InnovAge and 2 mentions for Oncology Institute. InnovAge's average media sentiment score of 0.65 beat Oncology Institute's score of 0.00 indicating that InnovAge is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
InnovAge
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Oncology Institute
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: InnovAge has a beta of 0.49, suggesting that its share price is 51% less volatile than the S&P 500. Comparatively, Oncology Institute has a beta of 0.33, suggesting that its share price is 67% less volatile than the S&P 500.
: InnovAge has higher revenue and earnings than Oncology Institute. Oncology Institute is trading at a lower price-to-earnings ratio than InnovAge, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
InnovAge $915.37M 1.18 -$30.31M $0.05 159.20
Oncology Institute $502.73M 0.78 -$60.61M -$0.56 N/A
: 12.3% of InnovAge shares are owned by institutional investors. Comparatively, 36.9% of Oncology Institute shares are owned by institutional investors. 1.0% of InnovAge shares are owned by insiders. Comparatively, 8.5% of Oncology Institute shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
: InnovAge currently has a consensus price target of $7.00, indicating a potential downside of 12.06%. Oncology Institute has a consensus price target of $7.00, indicating a potential upside of 75.88%. Given Oncology Institute's stronger consensus rating and higher possible upside, analysts clearly believe Oncology Institute is more favorable than InnovAge.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
InnovAge
1 Sell rating(s)
2 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.67
Oncology Institute
1 Sell rating(s)

0 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.60

Company	Net Margins	Return on Equity	Return on Assets
InnovAge	0.71%	2.60%	1.23%
Oncology Institute	-11.45%	N/A	-33.70%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InnovAge	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oncology Institute	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InnovAge	$915.37M	1.18	-$30.31M	$0.05	159.20
Oncology Institute	$502.73M	0.78	-$60.61M	-$0.56	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InnovAge	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Oncology Institute	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

InnovAge beats Oncology Institute on 11 of the 16 factors compared between the two stocks.

How does Oncology Institute compare to CareDx?

Oncology Institute (NASDAQ:TOI) and CareDx (NASDAQ:CDNA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.

: Oncology Institute currently has a consensus price target of $7.00, suggesting a potential upside of 75.88%. CareDx has a consensus price target of $25.00, suggesting a potential upside of 20.77%. Given Oncology Institute's stronger consensus rating and higher probable upside, equities analysts plainly believe Oncology Institute is more favorable than CareDx.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oncology Institute
1 Sell rating(s)
0 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.60
CareDx
1 Sell rating(s)

4 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
: CareDx has lower revenue, but higher earnings than Oncology Institute. CareDx is trading at a lower price-to-earnings ratio than Oncology Institute, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Oncology Institute $502.73M 0.78 -$60.61M -$0.56 N/A
CareDx $412.82M 2.59 -$21.35M -$0.16 N/A
: In the previous week, CareDx had 7 more articles in the media than Oncology Institute. MarketBeat recorded 9 mentions for CareDx and 2 mentions for Oncology Institute. CareDx's average media sentiment score of 0.44 beat Oncology Institute's score of 0.00 indicating that CareDx is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Oncology Institute
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
CareDx
1 Very Positive mention(s)
2 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: CareDx has a net margin of -2.01% compared to Oncology Institute's net margin of -11.45%. Oncology Institute's return on equity of 0.00% beat CareDx's return on equity.
Company Net Margins Return on Equity Return on Assets
Oncology Institute -11.45% N/A -33.70%
CareDx -2.01% -2.65% -1.96%
: Oncology Institute has a beta of 0.33, meaning that its share price is 67% less volatile than the S&P 500. Comparatively, CareDx has a beta of 2.49, meaning that its share price is 149% more volatile than the S&P 500.
: 36.9% of Oncology Institute shares are held by institutional investors. 8.5% of Oncology Institute shares are held by company insiders. Comparatively, 4.4% of CareDx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncology Institute	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
CareDx	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncology Institute	$502.73M	0.78	-$60.61M	-$0.56	N/A
CareDx	$412.82M	2.59	-$21.35M	-$0.16	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oncology Institute	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CareDx	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Oncology Institute	-11.45%	N/A	-33.70%
CareDx	-2.01%	-2.65%	-1.96%

Summary

Oncology Institute and CareDx tied by winning 8 of the 16 factors compared between the two stocks.

How does Oncology Institute compare to Teladoc Health?

Teladoc Health (NYSE:TDOC) and Oncology Institute (NASDAQ:TOI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

: Teladoc Health presently has a consensus price target of $7.53, suggesting a potential upside of 12.83%. Oncology Institute has a consensus price target of $7.00, suggesting a potential upside of 75.88%. Given Oncology Institute's stronger consensus rating and higher possible upside, analysts clearly believe Oncology Institute is more favorable than Teladoc Health.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Teladoc Health
1 Sell rating(s)
12 Hold rating(s)

5 Buy rating(s)

0 Strong Buy rating(s)
2.22
Oncology Institute
1 Sell rating(s)

0 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.60
: Oncology Institute has lower revenue, but higher earnings than Teladoc Health. Oncology Institute is trading at a lower price-to-earnings ratio than Teladoc Health, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Teladoc Health $2.51B 0.48 -$200.32M -$0.97 N/A
Oncology Institute $502.73M 0.78 -$60.61M -$0.56 N/A
: In the previous week, Teladoc Health had 26 more articles in the media than Oncology Institute. MarketBeat recorded 28 mentions for Teladoc Health and 2 mentions for Oncology Institute. Teladoc Health's average media sentiment score of 0.20 beat Oncology Institute's score of 0.00 indicating that Teladoc Health is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Teladoc Health
8 Very Positive mention(s)
3 Positive mention(s)
7 Neutral mention(s)
2 Negative mention(s)
3 Very Negative mention(s)
Neutral
Oncology Institute
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Teladoc Health has a net margin of -6.81% compared to Oncology Institute's net margin of -11.45%. Oncology Institute's return on equity of 0.00% beat Teladoc Health's return on equity.
Company Net Margins Return on Equity Return on Assets
Teladoc Health -6.81% -11.45% -5.54%
Oncology Institute -11.45% N/A -33.70%
: Teladoc Health has a beta of 2.08, suggesting that its stock price is 108% more volatile than the S&P 500. Comparatively, Oncology Institute has a beta of 0.33, suggesting that its stock price is 67% less volatile than the S&P 500.
: 76.8% of Teladoc Health shares are owned by institutional investors. Comparatively, 36.9% of Oncology Institute shares are owned by institutional investors. 0.7% of Teladoc Health shares are owned by insiders. Comparatively, 8.5% of Oncology Institute shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teladoc Health	1 Sell rating(s)	12 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.22
Oncology Institute	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teladoc Health	$2.51B	0.48	-$200.32M	-$0.97	N/A
Oncology Institute	$502.73M	0.78	-$60.61M	-$0.56	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Teladoc Health	8 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	3 Very Negative mention(s)	Neutral
Oncology Institute	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Teladoc Health	-6.81%	-11.45%	-5.54%
Oncology Institute	-11.45%	N/A	-33.70%

Summary

Teladoc Health beats Oncology Institute on 9 of the 16 factors compared between the two stocks.

How does Oncology Institute compare to The Pennant Group?

The Pennant Group (NASDAQ:PNTG) and Oncology Institute (NASDAQ:TOI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

: 85.9% of The Pennant Group shares are owned by institutional investors. Comparatively, 36.9% of Oncology Institute shares are owned by institutional investors. 6.9% of The Pennant Group shares are owned by insiders. Comparatively, 8.5% of Oncology Institute shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
: The Pennant Group has a beta of 1.28, suggesting that its stock price is 28% more volatile than the S&P 500. Comparatively, Oncology Institute has a beta of 0.33, suggesting that its stock price is 67% less volatile than the S&P 500.
: The Pennant Group has higher revenue and earnings than Oncology Institute. Oncology Institute is trading at a lower price-to-earnings ratio than The Pennant Group, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
The Pennant Group $947.71M 1.16 $29.58M $0.83 37.90
Oncology Institute $502.73M 0.78 -$60.61M -$0.56 N/A
: In the previous week, The Pennant Group had 5 more articles in the media than Oncology Institute. MarketBeat recorded 7 mentions for The Pennant Group and 2 mentions for Oncology Institute. The Pennant Group's average media sentiment score of 0.44 beat Oncology Institute's score of 0.00 indicating that The Pennant Group is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
The Pennant Group
2 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Oncology Institute
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: The Pennant Group has a net margin of 3.12% compared to Oncology Institute's net margin of -11.45%. The Pennant Group's return on equity of 10.10% beat Oncology Institute's return on equity.
Company Net Margins Return on Equity Return on Assets
The Pennant Group 3.12% 10.10% 4.32%
Oncology Institute -11.45% N/A -33.70%
: The Pennant Group presently has a consensus price target of $37.00, suggesting a potential upside of 17.61%. Oncology Institute has a consensus price target of $7.00, suggesting a potential upside of 75.88%. Given Oncology Institute's higher possible upside, analysts clearly believe Oncology Institute is more favorable than The Pennant Group.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
The Pennant Group
0 Sell rating(s)
1 Hold rating(s)

7 Buy rating(s)

0 Strong Buy rating(s)
2.88
Oncology Institute
1 Sell rating(s)

0 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.60

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
The Pennant Group	$947.71M	1.16	$29.58M	$0.83	37.90
Oncology Institute	$502.73M	0.78	-$60.61M	-$0.56	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
The Pennant Group	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oncology Institute	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
The Pennant Group	3.12%	10.10%	4.32%
Oncology Institute	-11.45%	N/A	-33.70%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
The Pennant Group	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
Oncology Institute	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

The Pennant Group beats Oncology Institute on 14 of the 16 factors compared between the two stocks.

How does Oncology Institute compare to Fortrea?

Oncology Institute (NASDAQ:TOI) and Fortrea (NASDAQ:FTRE) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

: In the previous week, Fortrea had 11 more articles in the media than Oncology Institute. MarketBeat recorded 13 mentions for Fortrea and 2 mentions for Oncology Institute. Fortrea's average media sentiment score of 0.50 beat Oncology Institute's score of 0.00 indicating that Fortrea is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Oncology Institute
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Fortrea
2 Very Positive mention(s)
3 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: 36.9% of Oncology Institute shares are held by institutional investors. 8.5% of Oncology Institute shares are held by company insiders. Comparatively, 0.4% of Fortrea shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
: Oncology Institute has a net margin of -11.45% compared to Fortrea's net margin of -36.21%. Fortrea's return on equity of 6.23% beat Oncology Institute's return on equity.
Company Net Margins Return on Equity Return on Assets
Oncology Institute -11.45% N/A -33.70%
Fortrea -36.21% 6.23% 1.42%
: Oncology Institute has a beta of 0.33, suggesting that its stock price is 67% less volatile than the S&P 500. Comparatively, Fortrea has a beta of 1.92, suggesting that its stock price is 92% more volatile than the S&P 500.
: Oncology Institute currently has a consensus price target of $7.00, suggesting a potential upside of 75.88%. Fortrea has a consensus price target of $16.05, suggesting a potential upside of 10.46%. Given Oncology Institute's stronger consensus rating and higher possible upside, equities analysts plainly believe Oncology Institute is more favorable than Fortrea.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oncology Institute
1 Sell rating(s)
0 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.60
Fortrea
1 Sell rating(s)

5 Hold rating(s)

5 Buy rating(s)

0 Strong Buy rating(s)
2.36
: Oncology Institute has higher earnings, but lower revenue than Fortrea. Oncology Institute is trading at a lower price-to-earnings ratio than Fortrea, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Oncology Institute $502.73M 0.78 -$60.61M -$0.56 N/A
Fortrea $2.72B 0.50 -$986.20M -$10.91 N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oncology Institute	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Fortrea	2 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Net Margins	Return on Equity	Return on Assets
Oncology Institute	-11.45%	N/A	-33.70%
Fortrea	-36.21%	6.23%	1.42%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncology Institute	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Fortrea	1 Sell rating(s)	5 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.36

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncology Institute	$502.73M	0.78	-$60.61M	-$0.56	N/A
Fortrea	$2.72B	0.50	-$986.20M	-$10.91	N/A

Summary

Oncology Institute and Fortrea tied by winning 8 of the 16 factors compared between the two stocks.

Get Oncology Institute News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TOI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TOI vs. The Competition

Export

Metric	Oncology Institute	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$393.38M	$8.11B	$6.25B	$11.87B
Dividend Yield	N/A	2.18%	2.73%	5.21%
P/E Ratio	-7.11	24.84	29.04	28.48
Price / Sales	0.78	17.51	476.48	60.89
Price / Cash	N/A	13.23	27.62	36.52
Price / Book	-24.88	4.94	9.67	6.67
Net Income	-$60.61M	$183.43M	$3.55B	$332.64M
7 Day Performance	15.70%	0.20%	1.70%	2.01%
1 Month Performance	27.56%	5.27%	5.62%	9.19%
1 Year Performance	50.19%	0.38%	34.42%	39.59%

Oncology Institute Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TOI Oncology Institute	2.8374 of 5 stars	$3.98 -2.5%	$7.00 +75.9%	N/A	$393.38M	$502.73M	N/A	660	Upcoming Earnings
INNV InnovAge	1.4637 of 5 stars	$8.27 +2.2%	$7.00 -15.4%	N/A	$1.12B	$853.70M	165.43	2,440	News Coverage Earnings Report
CDNA CareDx	2.5526 of 5 stars	$21.91 +0.3%	$27.60 +26.0%	N/A	$1.12B	$379.80M	N/A	740	Earnings Report Analyst Upgrade
TDOC Teladoc Health	2.6468 of 5 stars	$6.01 +2.6%	$7.62 +26.9%	N/A	$1.08B	$2.53B	N/A	5,600	Earnings Report Analyst Forecast
PNTG The Pennant Group	3.4506 of 5 stars	$30.79 -0.3%	$37.00 +20.2%	N/A	$1.08B	$947.71M	37.10	9,700	News Coverage Positive News Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TOI) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oncology Institute (TOI) Competitors

TOI vs. INNV, CDNA, TDOC, PNTG, and FTRE

How does Oncology Institute compare to InnovAge?

Summary

How does Oncology Institute compare to CareDx?

Summary

How does Oncology Institute compare to Teladoc Health?

Summary

How does Oncology Institute compare to The Pennant Group?

Summary

How does Oncology Institute compare to Fortrea?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TOI vs. The Competition

Oncology Institute Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oncology Institute (TOI) Competitors

TOI vs. INNV, CDNA, TDOC, PNTG, and FTRE

How does Oncology Institute compare to InnovAge?

Summary

How does Oncology Institute compare to CareDx?

Summary

How does Oncology Institute compare to Teladoc Health?

Summary

How does Oncology Institute compare to The Pennant Group?

Summary

How does Oncology Institute compare to Fortrea?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TOI vs. The Competition

Oncology Institute Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools